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Dectin-1 is a C-type lectin receptor critical in anti-
fungal immunity, but Dectin-1 has not been linked
to regulation of sterile inflammation or oncogenesis.
We found that Dectin-1 expression is upregulated in
hepatic fibrosis and liver cancer. However, Dectin-1
deletion exacerbates liver fibro-inflammatory dis-
ease and accelerates hepatocarcinogenesis. Mecha-
nistically, we found that Dectin-1 protects against
chronic liver disease by suppressing TLR4 signaling
in hepatic inflammatory and stellate cells. Accord-
ingly,Dectin-1–/–mice exhibited augmented cytokine
production and reduced survival in lipopolysaccha-
ride (LPS)-mediated sepsis, whereas Dectin-1 acti-
vation was protective. We showed that Dectin-1
inhibits TLR4 signaling by mitigating TLR4 and
CD14 expression, which are regulated by Dectin-1-
dependent macrophage colony stimulating factor
(M-CSF) expression. Our study suggests that
Dectin-1 is an attractive target for experimental ther-
apeutics in hepatic fibrosis and neoplastic transfor-
mation. More broadly, our work deciphers critical
cross-talk between pattern recognition receptors
and implicates a role for Dectin-1 in suppression of
sterile inflammation, inflammation-induced onco-
genesis, and LPS-mediated sepsis.INTRODUCTION
Hepatic fibrosis—the end result of repeated liver injury—is one of
the most significant public health concerns worldwide (Lim and
Kim, 2008). Liver injury resulting from a variety of etiologies,
including viral hepatitis, toxins, or metabolic disorders, primesCell Rehepatocytes to regenerate to replace necrotic or apoptotic he-
patic parenchymal cells and simultaneously triggers a robust in-
flammatory response, which induces hepatic stellate cells
(HSCs) to transdifferentiate and express extracellular matrix
(ECM) proteins. If injury persists, regeneration eventually fails,
and the hepatocytes are replaced by abundant ECM leading to
fibrosis and eventually cirrhosis (Bataller and Brenner, 2005).
Liver fibrosis is clinically associated with the development of he-
patocellular carcinoma (HCC), the third leading cause of cancer-
related death worldwide (Franceschi and Raza, 2009).
Toll-like receptor (TLR) ligation is a primary mechanism by
which intra-hepatic innate inflammatory cells and HSCs are acti-
vated after hepatic injury (Paik et al., 2003; Seki et al., 2007).
TLRs belong to a broader category of evolutionarily conserved
pattern recognition receptors (PRRs), which link inflammatory re-
sponses to pathogenic or sterile inflammatory stimuli (Kawai and
Akira, 2010). A primary role of TLR4 expressed on innate hepatic
leukocytes is to respond to lipopolysaccharide (LPS) (De Creus
et al., 2005). In addition, in the context of chronic liver injury,
TLRs can ligate intra-hepatic ‘‘danger molecules,’’ which include
by-products of inflammatory injury and cellular necrosis, collec-
tively denoted damage-associated molecular patterns (DAMPs)
(Paik et al., 2003; Seki et al., 2007). As such, TLR ligation has a
critical role in perpetuating sterile inflammation and tissue dam-
age in chronic liver disease. For example, ligation of either TLR4
or TLR9 markedly promotes liver fibrosis, whereas deletion of
either receptor is protective (Aoyama et al., 2010). Similarly,
TLR4 ligation by LPS derived from selected intestinal microbiota
promotes hepatocellular carcinogenesis (Dapito et al., 2012).
Dectin-1 is a trans-membrane receptor and member of the
C-type Lectin family of PRRs. Dectin-1 is required for the innate
immune response to fungal pathogens (Vautier et al., 2012).
Ligation of fungal wall b-glucans by Dectin-1 recruits the
CARD9 adaptor protein, which phosphorylates Syk, thereby initi-
ating an anti-fungal immune response (Gross et al., 2006;
Strasser et al., 2012). However, Dectin-1 does not have an es-
tablished role in modulating sterile inflammation in liver fibrosisports 13, 1909–1921, December 1, 2015 ª2015 The Authors 1909
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or in any physiologic context. Our preliminary findings revealed
that Dectin-1 is highly upregulated in liver fibrosis and in HCC
in both mice and humans. Based on these data, we postulated
that Dectin-1 signaling modulates hepatic fibro-inflammatory
disease and oncogenesis. We found that Dectin-1 deletion ac-
celerates hepatic fibrosis and hepatocellular tumorigenesis,
whereas Dectin-1 ligation is protective. Our mechanistic work
suggests that Dectin-1 protects against liver fibrosis via sup-
pression of TLR4 activation by directly mitigating expression of
TLR4 and its co-receptor CD14. We show that Dectin-1 modula-
tion of CD14 expression on hepatic innate inflammatory cells is
contingent on macrophage colony stimulating factor (M-CSF).
This is direct evidence of a role for Dectin-1 in non-pathogen-
driven sterile inflammation and suggests that targeting Dectin-1
may be an attractive strategy for experimental therapeutics in
hepatic fibrosis and HCC. Moreover, our work has pleiotropic
implications for understanding reciprocal regulation between
families of PRRs, which is critical for maintaining physiologic ho-
meostasis in health and disease.
RESULTS
Dectin-1 Expression Is Increased in Liver Fibrosis
To assess the potential impact of Dectin-1 signaling in liver dis-
ease, we examined Dectin-1 expression in both hepatic inflam-
matory and parenchymal cells. Liver leukocytes, specifically
dendritic cells (DCs) and macrophages, expressed high Dec-
tin-1 compared with their counterparts in the murine spleen (Fig-
ure 1A). Similarly, human liver leukocytes, and in particular
CD14+ monocytic cells, expressed elevated Dectin-1 compared
with peripheral blood mononuclear cells (PBMCs) (Figure 1B).
Hepatic stellate cells also expressed high Dectin-1 on immune-
fluorescence microscopy and flow cytometry (Figure 1C).
Conversely, liver parenchymal cells, including hepatocytes and
liver sinusoidal endothelial cells, expressed minimal Dectin-1
(Figure 1D). Moreover, in hepatic fibrosis, Dectin-1 expression
was upregulated in hepatic DC (Figure 1E) and macrophages
(Figure 1F) compared with their expression in normal liver.
Accordingly, both murine (Figure 1G) and human (Figure 1H) liver
fibrosis were associatedwith a robust intra-hepatic influx of Dec-
tin-1+ cells.Figure 1. High Dectin-1 Expression in Hepatic Leukocytes and in Liver
(A) Liver non-parenchymal cell (NPC) suspensions fromWTmice were tested for c
Similarly, Dectin-1 expression was tested in murine WT and Dectin-1–/– fib
(CD11c-Gr1-F480+CD11b+) compared with their counterparts in spleen by flow cy
summary data from five separate experiments are shown.
(B) Human liver NPC were tested for co-expression of Dectin-1 and CD11b by c
CD45+ pan-leukocytes and CD14+ monocytes was compared in human liver versu
shown.
(C) Dectin-1 expression was tested in cultured murine hepatic stellate cells by bot
isotype control (scale bar, 10 mm).
(D) Murine CD45–CD146+ liver sinusoidal endothelial cells (LSECs) and CD45–C
Dectin-1 compared with isotype control (gray histogram).
(E and F) Expression of Dectin-1 was tested in CD11c+MHCII+ DC (E) and CD11c
with TAA-induced liver fibrosis compared with isotype control. Representative d
(G and H) Normal and fibrotic murine (G) and human liver (H) were tested for infiltra
(scale bar, 100 mm).
Each experiment was repeated at least three times with similar results (*p < 0.05
Cell ReDectin-1 Regulates Hepatic Fibrosis
To test the importance of Dectin-1 signaling in modulating
chronic liver disease, we induced hepatic fibrosis in wild-type
(WT) or Dectin-1–/– mice using Thioacetamide (TAA) or Carbon
tetrachloride (CCl4). Non-fibrotic WT and Dectin-1
–/– livers
exhibited indistinguishable hepatic phenotypes (Figure S1).
However, Dectin-1-deficient livers developedmarkedly exagger-
ated hepatic fibrosis on histologic analysis in both the TAA (Fig-
ures 2A and 2B) and CCl4 (Figures S2A–S2D) disease models.
Serum transaminase levels were not differentially elevated in
Dectin-1–/– animals (Figures 2C, 2D, and S2C). Western blotting
confirmed higher hepatic expression of extracellular matrix
(ECM) proteins TIMP2, TIMP4,MMP7, andMMP2 in TAA-treated
Dectin-1–/– liver compared with WT (Figure 2E). Genes that regu-
late ECM remodeling were also expressed at higher levels in
fibrotic Dectin-1–/– liver on RT-PCR analysis (Figure 2F). Accord-
ingly, a-SMA expression was elevated in fibroticDectin-1–/– liver,
indicative of enhanced HSC activation (Figure 2G). Furthermore,
consistent with more advanced disease (Kuramitsu et al., 2013),
therewas diminished hepatocyte proliferation in the regenerative
nodulesof fibroticDectin-1–/– liver comparedwithWT (Figure2H).
Notably, mice deficient in Mincle—a C-type lectin receptor akin
toDectin-1—did not exhibit exacerbated hepatic fibro-inflamma-
tory disease after hepatotoxin treatment suggesting specificity of
the effect to Dectin-1 (Figures S2E–S2G).
Dectin-1 Regulates Intra-hepatic Inflammation
To testwhetherDectin-1 suppresseshepatic inflammation in liver
fibrosis, we analyzed the comparative innate immune infiltrates in
TAA- or CCl4-treated WT and Dectin-1
–/– liver. Fibrotic Dec-
tin-1–/– liver exhibited a higher pan-leukocyte infiltrate (Figures
3A, S2A, and S2D), greater neutrophilia (Figure 3B), and a higher
influx of CD68+ macrophages (Figure 3C) compared with WT.
Consistent with these findings, serum levels of MCP-1 were
elevated in fibroticDectin-1–/– liver (Figure 3D). We previously re-
ported that,whereasDCdonot directly influencehepatic fibrosis,
they are critical orchestrators of hepatic inflammation in the
fibrotic liver via tumor necrosis factor a (TNF-a) production (Con-
nolly et al., 2009). Accordingly, we found that the fraction of DC
was increased in the liver of TAA-treated Dectin-1–/– mice
compared with WT (Figure 3E). Further, intracellular cytokineFibrosis in Mice and Humans
o-expression of Dectin-1 and CD68 by confocal microscopy (scale bar, 10 mm).
rotic liver CD45+ pan-leukocytes, DC (CD11c+MHCII+), and macrophages
tometry. Gray histograms represent isotype controls. Representative data and
onfocal microscopy (scale bar, 10 mm). The fraction of Dectin-1+ cells among
s PBMC by flow cytometry. Representative histograms and summary data are
h confocal microscopy and flow cytometry compared withDectin-1–/–HSC and
D146– hepatocytes derived from fibrotic liver were tested for expression of
–Gr1–F480+CD11b+ (F) macrophages from control liver versus liver from mice
ata and summary data from three experiments are shown.
tion of Dectin-1+ cells by immunohistochemistry compared with isotype control
, **p < 0.01, ***p < 0.001,****p < 0.0001).
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Figure 2. Dectin-1 Deletion Exacerbates Hepatic Fibrosis
WT and Dectin-1–/– mice were treated with TAA for 12 weeks.
(A) Livers were harvested and analyzed by H&E, Trichrome, and Sirius Red staining (scale bar, 1 mm).
(B) Fibrosis was quantified based on Trichrome staining using a computerized grid.
(legend continued on next page)
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Figure 3. Dectin-1 Regulates Intra-Hepatic
Inflammation in Fibrotic Liver
(A–C) WT and Dectin-1–/– mice were treated with
TAA for 12 weeks. Livers were harvested and
analyzed for infiltration with (A) CD45+ pan-leuko-
cytes, (B) MPO+ neutrophils, and (C) CD68+
macrophages (scale bar, 100 mm) by immunohis-
tochemistry. Representative images and summary
data are shown.
(D) Serum MCP-1 levels were measured in control
and fibrotic WT and Dectin-1–/– liver.
(E) The fraction of DC in hepatic NPC suspensions
was compared in PBS- and TAA-treated WT and
Dectin-1–/– liver.
(F and G) Liver MHC II+ APC from control and TAA-
treated WT and Dectin-1–/– liver were tested for (F)
expression of IL-6 and (G) TNF-a using intracellular
cytokine analysis.
Each experiment was repeated more than three
times with similar results (n = 6 mice/group;
**p < 0.01).analysis showed markedly higher interleukin 6 (IL-6) (Figure 3F)
and TNF-a (Figure 3G) expression in APC in fibrotic Dectin-1–/–
liver compared with WT. Collectively, these data suggest that
deletion of Dectin-1 results in an expanded and more activated
innate inflammatory infiltrate in hepatic fibrosis.
To further assess the effect of Dectin-1 deletion on intra-he-
patic inflammation in liver fibrosis, we tested hepatic expression
of inflammatory mediators by nanostring analysis. The comple-
ment system has recently been demonstrated to play a critical
role in the pathogenesis of liver fibrosis in mice and humans (Va-
sel et al., 2014). We found higher expression of multiple compo-
nents of the complement system in fibrotic Dectin-1–/– liver(C–F) Serum levels of ALT and AST (D) were analyzed. Liver tissues were tested for (E) expression of TIMP2, TI
(F) expression of Plau, Thbs1, Serpine1, and Mmp9 by RT-PCR.
(G and H) HSC activation in TAA-treated WT and Dectin-1–/– liver was tested by expression of a-SMA (scale
assessed using PCNA immunohistochemistry (H) (n = 20 mice/group; *p < 0.05, **p < 0.01).
Cell Reports 13, 1909–1921, Dcompared with WT (Figure S3A). Further,
Dectin-1 deletion in liver fibrosis resulted
in exaggerated expression of pro-in-
flammatory chemokines (Figure S3B), a
diverse array of chemokine receptors (Fig-
ure S3C), and genes associated with IL-1,
IL-6, and TGF-b signaling (Figure S3D).
Notably, expression levels of soluble
inflammatory mediators and chemokine
receptors were not significantly different
between PBS-treated WT and Dectin-1–/–
liver (Figure S1D). To determine in which
compartment Dectin-1 signaling modu-
lated liver fibrosis, we irradiated WT and
Dectin-1–/– mice and made these animals
chimeric using bone marrow derived
from WT and Dectin-1–/– donors before
inducing TAA-mediated liver fibrosis
7 weeks later. Our extent of chimerismwas 95% (Figure S3E). We found that Dectin-1 deletion in
both the radio-sensitive and radio-resistant compartments had
additive effects on exacerbating fibrosis (Figure S3F).
Dectin-1 Protects against Hepatocellular
Carcinogenesis
Hepatocellular carcinoma (HCC) develops almost exclusively in
the setting of chronic liver disease (El-Serag, 2007). We found
that HCC in humans is associated with a robust infiltrate of
Dectin-1+ leukocytes (Figure 4A). Tumor cells did not express
Dectin-1 (Figures 4A and 4B). However, murine DC and macro-
phages upregulated their expression of Dectin-1 in HCC nodulesMP4,MMP7, andMMP2 bywestern blotting and for
bar, 100 mm) (G), and hepatocyte proliferation was
ecember 1, 2015 ª2015 The Authors 1913
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Figure 4. Dectin-1 Deletion Promotes Hepa-
tocarcinogenesis
(A) Dectin-1 expression was tested by immunohis-
tochemistry in human HCC. Representative inter-
stitial and tumor cell-rich areas are shown (scale
bar, 100 mm).
(B) Tumor nodules were digested with collagenase,
and CD45– cells were tested for Dectin-1 expres-
sion compared with isotype control.
(C) Dectin-1 expression was compared in
CD11c+MHCII+ DC and Gr1–CD11c–F4/80+CD11b+
macrophages from control liver versus HCC nod-
ules in mice. Representative data and summary
data from three animals are shown.
(D) WT and Dectin-1–/– mice were treated with
CCl4 + DEN. Representative images of mice and
liver tumors at 24 weeks are shown. The percentage
of liver weight per body weight, the maximal diam-
eter of the largest tumor in each animal, and the
number of surface liver tumors per mouse were
calculated.
(E) Tumors were tested for expression of NF-kB and
MAP Kinase signaling intermediates, MyD88, and
TRAF6 by western blotting. Representative data
and density plots based on triplicates are shown.
(F) Tumors were tested for oncogenic genes using a
RT-PCR array (n = 6 mice/group; *p < 0.05,
**p < 0.01).comparedwith normal liver (Figure 4C). Therefore, we postulated
that, besides modulating liver fibrosis, Dectin-1 may also regu-
late hepatocellular oncogenesis. Mice were induced to develop
HCC using diethylnitrosamine (DEN) and CCl4. WT and Dec-
tin-1–/– animals did not exhibit differential acute responses to
DEN (data not shown). However, Dectin-1–/– mice developed
accelerated hepatocellular carcinogenesis based on liver
weight, tumor size, and number of nodules (Figure 4D). Western
blotting revealed evidence of higher MAP kinase and NF-kB
signaling in Dectin-1–/– HCC tumor nodules, consistent with an
aggressive malignant phenotype (Hsu et al., 1993; Nishida
et al., 1994) (Figure 4E), whereas inflammatory signaling was
similar in PBS-treated WT and Dectin-1–/– liver (Figure S1E).
MyD88 and TRAF6 expression were also elevated in Dectin-1–/–
tumor nodules (Figure 4E). Further, PCR array analysis showed
that Cdkn1, Cdkn2, and Serpinb5—whose reduced expression
is associated with a more aggressive HCC phenotype (Fujisawa
et al., 2005; Hu et al., 2011; Hui et al., 2008)—were each ex-
pressed at lower levels in Dectin-1–/– tumors compared with
WT (Figure 4F).
Dectin-1 Suppresses TLR4 Activation
Dectin-1 has not previously been linked to sterile inflammation or
oncogenesis. However, TLR4 activation in the liver is central to1914 Cell Reports 13, 1909–1921, December 1, 2015 ª2015 The Authorsthe progression of hepatic fibro-inflamma-
tory disease and carcinoma (Dapito et al.,
2012; Seki et al., 2007). We found that
TLR4 and Dectin-1 co-associate in liver in-
flammatory cells as evidenced by immuno-
precipitation experiments (Figures S4Aand S4B) and confocal microscopy (Figure S4C) suggesting op-
portunity for cross-regulation. Therefore, we postulated that
suppression of TLR4 signaling may be the mechanism of Dec-
tin-1-mediated protection in chronic liver disease. Consistent
with our hypothesis, inhibition of MyD88 (Figure S5A) or TLR4
(Figure 5A) abrogated the exacerbated fibrosis associated with
Dectin-1 deletion. To directly test whether Dectin-1 suppresses
TLR4 signaling, we induced endotoxemia by challengingWT and
Dectin-1–/– mice with TLR4 ligand LPS. Serum IL-6 levels were
substantially higher and more sustained in Dectin-1–/– mice
compared with WT (Figure 5B). Dectin-1–/– mice also exhibited
a sharper decrease in core temperature after LPS challenge sug-
gesting increased systemic toxicity resulting from TLR4 ligation
(Figure 5C). Moreover, Kaplan-Meier analysis revealed markedly
diminished survival in LPS-treatedDectin-1–/–mice compared to
WT (Figure 5D). Taken together, these data suggest that Dec-
tin-1 inhibits TLR4 activation in vivo. Similarly, in vitro LPS-treat-
ment of splenocytes from Dectin-1–/– mice resulted in higher
TNF-a production (Figure 5E) and proliferation (Figure 5F)
compared with WT. Splenocyte composition was similar in WT
and Dectin-1–/– animals (data not shown). LPS treatment of Dec-
tin-1–/–HSCs also resulted in higher TNF-a (Figure 5G), IL-6 (Fig-
ure 5H), and MCP-1 (Figure 5I) production compared with
LPS-treated WT HSCs. Notably, Dectin-1 deletion did not result
Figure 5. Dectin-1 Negatively Regulates
TLR4 Activation
(A) WT and Dectin-1–/– mice were treated for
12 weeks with a TLR4 inhibitor alone, TAA alone, or
both in combination (n = 5/group). Trichrome
staining of representative liver sections is shown,
and the fraction of fibrotic area was calculated for
each cohort using a computerized grid (scale bar,
10 mm).
(B–D) WT and Dectin-1–/– mice were treated with
LPS and assayed for (B) serum levels of IL-6, (C)
core body temperature at serial time intervals, and
(D) survival (n = 6 mice/group).
(E and F) Splenocyte suspensions derived from WT
and Dectin-1–/– mice were treated in vitro with PBS
or LPS and tested for both (E) TNF-a production in
cell-culture supernatant and (F) cellular prolifera-
tion.
(G–I) HSCs derived from WT and Dectin-1–/– mice
were treated in vitro with PBS or LPS and tested for
production of (G) TNF-a, (H) IL-6, and (I) MCP-1 in
cell-culture supernatant.
(J) Fibrotic Dectin-1–/– and WT liver tissue were
assayed for expression of activated signaling in-
termediates downstream of TLR4 ligation by west-
ern blotting.
Representative data and density plots based on
quadruplicates are shown. In vitro experiments
were repeated at least three times using three to five
mice per experimental group (*p < 0.05, **p < 0.01,
***p < 0.001).in upregulated cytokine responses to TLR2 (HKLM) ligation (data
not shown).
To test for evidence of Dectin-1 suppression of TLR4 signaling
in hepatic fibrosis, tissues from fibrotic WT and Dectin-1–/– liver
were probed for expression of TLR4-related signaling intermedi-
ates. We found elevated expression of TRAF6, MyD88, and acti-
vated NF-kB and MAP Kinase signaling intermediates in fibrotic
Dectin-1–/– liver compared with WT (Figure 5J), consistent with
higher TLR4 activation. Conversely, the TRIF adaptor protein
was expressed at similar levels in both groups (Figure 5J).
Dectin-1 Critically Regulates Expression of TLR4
and CD14
We postulated that Dectin-1 may modulate TLR4 activation by
suppressing TLR4 expression. Consistent with our hypothesis,
whereas TLR4 was expressed at similar levels in PBS-treated
WT andDectin-1–/– hepatic APC, in liver fibrosis TLR4 was differ-
entially upregulated in Dectin-1–/–macrophages (Figure 6A)Cell Reports 13, 1909–1921, Dcompared with WT. Further, CD14—a crit-
ical co-receptor for TLR4 (Zanoni et al.,
2009)—was also expressed at elevated
levels in in macrophages derived from
fibrotic Dectin-1–/– liver (Figure 6B). Similar
upregulations in TLR4 and CD14 expres-
sion were seen in Dectin-1–/– DC (data
not shown) and on PCR of fibrotic whole-
liver specimens (Figure S6A). Analysis of
murine HCC tumors also revealed elevatedCd14 expression in Dectin-1–/– tumor nodules compared with
WT (Figure S6B). By contrast, Dectin-1 ligation using a variety
of ligands substantially lowered macrophage expression of
TLR4 (Figure 6C) and CD14 (Figure 6D). Further, Dectin-1 ligation
in vivo protected animals from LPS-induced endotoxemia (Fig-
ures 6E and 6F) and liver fibro-inflammation (Figures 6G and
6H). Notably, Dectin-1–/– macrophages or DC did not exhibit
elevated expression of TLR2 in hepatic fibrosis (Figures S6C
and S6D) or after stimulation with TLR2 ligand HKLM compared
with WT (data not shown).
To test whether Dectin-1 suppression of CD14 expression is a
primary mechanism in the capacity of Dectin-1 to mitigate
TLR4 responsiveness, we blocked CD14 in vivo coincident
with PBS or LPS challenge in WT and Dectin-1–/– mice. CD14
blockade had no discernible effect in PBS-treated WT or Dec-
tin-1–/– mice (Figures S6E and S6F). However, blockade of
CD14 abrogated the augmented LPS-mediated inflammatory re-
sponses (Figure 6I) and systemic toxicity (Figure 6J) exclusivelyecember 1, 2015 ª2015 The Authors 1915
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Figure 6. Dectin-1 Suppresses TLR4 and
CD14 Expression, which Mediates Dectin-1
Regulation of Liver Fibrosis and Inflam-
mation
(A and B) WT and Dectin-1–/– mice were treated
for 12 weeks with PBS or TAA. CD11c–Gr1–
F480+CD11b+ macrophages were tested for (A)
TLR4 and (B) CD14 expression by flow cytometry.
Representative data and summary data from five
mice per group are shown.
(C and D) Macrophages were stimulated in vitro for
24 hr with an array of Dectin-1 ligands and then
tested for expression of (C) TLR4 and (D) CD14.
(E) WTmice were challenged in vivo with LPS alone
or in combination with an array of selective Dec-
tin-1 ligands or vehicle. Core body temperature
was measured at 12 hr.
(F) WTmice were challenged in vivo with LPS alone
or LPS + Curdlan. Serum cytokines were measured
at 12 hr (error bar, 1 mm).
(G and H) WT mice were treated for 12 weeks with
PBS, depleted Zymosan alone, TAA alone, or
depleted Zymosan + TAA. Trichrome staining of
representative liver sections are shown, and the
fraction of fibrotic area was calculated for each
cohort using a computerized grid. (H) Serum levels
of MCP-1 were calculated (n = 5/group).
(I and J) WT and Dectin-1–/– mice were challenged
in vivo with LPS alone or LPS + CD14 blockade (n =
5/group). Effects of CD14 inhibition on (I) lowering
serum levels of TNF-a and IL-6 and (J) increasing
core body temperature compared with LPS treat-
ment alone are shown (error bar, 1 mm).
(K) TAA-treated WT and Dectin-1–/– mice were
administered isotype or a neutralizing a-CD14mAb
during the 12-week course of fibrosis induction.
Trichrome staining of representative liver sections
are shown, and the fraction of fibrotic area was
calculated for each cohort using a computerized
grid (n = 4/group; *p < 0.05, **p < 0.01,
***p < 0.001).in Dectin-1–/– animals. Moreover, CD14 blockade was markedly
protective against hepatic fibrosis in TAA-treated Dectin-1–/–
liver, whereas CD14 inhibition had imperceptible effects in WT
liver (Figure 6K). Similarly, CD14 inhibition reduced APC activa-
tion in fibroticDectin-1–/– liver but did not have anti-inflammatory
effects in fibrotic WT liver (Figure S6G). In our parallel in vitro ex-
periments, CD14 blockade was alsomore inhibitory in LPS-stim-
ulated Dectin-1–/– HSCs compared with WT HSCs in terms of
cellular activation (pPDGFR) and ECM protein production
(MMP7, MMP9, TIMP2) (Figure S6H). Collectively, these data
imply that Dectin-1 regulates TLR4 signaling in LPS sepsis as
well as in liver fibrosis by modulating CD14 levels.
M-CSF Promotes CD14 Expression in Dectin-1–/– Liver
M-CSF can have pleiotropic effects on APC function and has
recently been shown to promote fibrosis in cases of HCV infec-
tion (Kwan et al., 2007; Preisser et al., 2014). We discovered that
deletion of Dectin-1 in the fibrotic liver increased expression of1916 Cell Reports 13, 1909–1921, December 1, 2015 ª2015 The AutM-CSF in hepatic inflammatory and parenchymal cells based
on immunohistochemical (Figure 7A) andmRNA (Figure S3B) an-
alyses. Dectin-1 deletion also upregulated M-CSF receptor
CD115 expression in HSC cultures (Figure S7A) and in liver
APC (Figure S7B). By contrast, Dectin-1 ligation lowered
M-CSF expression in vivo after LPS treatment (Figure 7B). We
found that Protein Kinase C (PKC)—which can regulate M-CSF
activity (Whetton et al., 1994)—was upregulated in the context
of Dectin-1 deletion (Figure S7C) and PKC inhibition abrogated
the higher M-CSF expression (Figure S7D). We postulated that
augmentedM-CSF signaling is responsible for the pathologically
high CD14 expression and the exacerbated hepatic fibrosis in
Dectin-1–/– liver. Consistent with our hypothesis, in vivo M-CSF
blockade during fibrogenesis resulted in markedly lower CD14
expression in Dectin-1–/– hepatic APC with smaller effects in
WT (Figure 7C). Similarly, in vitro M-CSF blockade mitigated
the higher CD14 expression in LPS-stimulated Dectin-1–/–
macrophages but had negligible effects in WT (Figure S7E).hors
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Figure 7. M-CSF Blockade Lowers CD14
Expression and Protects against Fibrosis
in Dectin-1–/– Liver
(A) Paraffin-embedded liver sections from PBS-
and TAA-treated WT and Dectin-1–/– mice were
stained using a mAb specific for M-CSF. Repre-
sentative images are shown (n = 5; scale bar,
100 mm).
(B) WT mice were challenged in vivo with LPS
alone or in combination with an array of selective
Dectin-1 ligands or vehicle. Serum M-CSF was
measured at 12 hr (n = 3 mice/group).
(C) WT and Dectin-1–/–mice were treated with TAA
for 12 weeks. Selected cohorts were additionally
treated with a-M-CSF or isotype control. DC and
macrophage subsets were gated by flow cy-
tometry and tested for expression of CD14.
Representative data from one liver and summary
data from five mice are shown (error bar, 1 mm).
(D) WT andDectin-1–/–mice were treated with PBS
or TAA for 12 weeks. Select cohorts were addi-
tionally treated with a-M-CSF or isotype control.
Liver sections were stained with Trichrome, and
fibrosis was quantified using a computerized grid.
(E and F) Macrophages were treated with PBS or
recombinant M-CSF and tested for (E) CD14
expression by flow cytometry and (F) TNF-a and
MCP-1 expression in cell-culture supernatant.
(G and H) WT mice were co-administered LPS and
M-CSF alone or in combination. (G) Serum levels
of IL-6 and (H) core body temperature were
measured (n = 5/group; *p < 0.05, **p < 0.01,
***p < 0.001).Moreover, similar to CD14 blockade, M-CSF inhibition amelio-
rated hepatic fibrosis in the setting of Dectin-1 deletion but
offered no protection in WT liver (Figure 7D). Conversely, treat-
ment with recombinant M-CSF increased CD14 expression
(Figure 7E) and upregulated MCP-1 and TNF-a expression in
macrophages in vitro (Figure 7F) and exacerbated LPS-medi-
ated sepsis in vivo (Figures 7G and 7H). TNF-a blockade pre-
vented the M-CSF-induced differential CD14 upregulation in
Dectin-1–/– macrophages (Figure S7F). Collectively, these data
suggest that Dectin-1-regulated expression of M-CSF drives
CD14-dependent exaggerated hepatic fibrosis and inflamma-
tory responses in LPS-mediated sepsis.
DISCUSSION
TLR4-mediated inflammation is critical in both host defense
against invading pathogens and for physiological responses to
inflammatory stimuli. However, regulation of TLR4 responses is
paramount in limiting end-organ injury and tissue damage inCell Reports 13, 1909–1921, Dsterile inflammatory processes such as
hepatic fibrosis, after septic injury, and
mitigating progression toward malig-
nancies in TLR4-dependent cancers
such as HCC (Lu et al., 2008; Peri and
Piazza, 2012). The understanding of
negative regulation of TLR4 signaling inany of these contexts is rudimentary. In general, suppression
of TLR signaling is thought to occur via three distinct mecha-
nisms: degradation of TLR-associated adaptor proteins, dissoci-
ation of TLR-dependent signaling complexes, and regulation of
transcription of soluble inflammatory mediators. Inhibitory pro-
teins SOCS1 and SOCS3 suppress TLR4 activation by promot-
ing the degradation of the MyD88 adaptor-like (MAL) or TRAF
proteins (Fujimoto and Naka, 2010; Yoshimura et al., 2004).
TANK and SHP1 each independently inhibit TRAF6 ubiquitina-
tion, and mice deficient in either of these proteins exhibit more
robust inflammatory responses to TLR ligands and readily prog-
ress to organ failure in diverse TLR-dependent disease models
(Kawagoe et al., 2009; Yuk et al., 2011). DAP12 and b2 integrins
cross-regulate TLR responses through promotion of IL-10
expression and via activation of the E3 ubiquitin ligase Cbl-b,
which degrades MyD88 and TRIF leading to reduced inflamma-
tion (Hamerman et al., 2005; Han et al., 2010; Wang et al., 2010;
Yee and Hamerman, 2013). Despite these varied mechanisms of
TLR regulation, cross-inhibition between individual or families ofecember 1, 2015 ª2015 The Authors 1917
PRRs is not well described. Our finding that Dectin-1 suppresses
TLR4 activation is evidence of negative regulation between
PRRs in an in vivomodel of sterile inflammation or LPS-mediated
endotoxemia. We show that Dectin-1 and TLR4 coassociate.
This raises the question of whether the Dectin-1/TLR4 complex
directly regulates TLR4 function; however, deciphering this re-
quires more exact experimentation. Previous reports have not
found augmented responses to TLR4 ligation in the context of
Dectin-1 deletion; however, discrepancies with the current
studies may be related to the substantially lower doses of LPS
utilized in the other reports and the bone marrow-derived DC
and macrophage models employed (Del Fresno et al., 2013;
Saijo et al., 2007).
Dectin-1 is vital in the innate immune defense against fungal
pathogens (Vautier et al., 2012). Patients with genetic defi-
ciencies in Dectin-1 are at high risk for recurrent mucocutaneous
fungal infections, such as vulvovaginal candidiasis or onychomy-
cosis (Ferwerda et al., 2009). However, unlike their TLR cousins,
a definitive role for Dectin-1 in non-pathogen mediated inflam-
mation is lacking (Bianchi, 2007). The present study describes
a protective role for Dectin-1 in liver fibrosis and hepatocarcino-
genesis and, more broadly, implicates a regulatory role for Dec-
tin-1 inmodulating sterile inflammation, the inflammation-cancer
paradigm, as well as LPS-mediated sepsis. We found that dele-
tion of Mincle, an allied C-type lectin receptor, has no effect on
liver fibrogenesis indicating that the observed effects are specific
to Dectin-1. These data suggest that modulating Dectin-1
signaling may be an attractive target in experimental therapeu-
tics in either inflammatory or infectious conditions mediated by
TLR4 ligation or in cases of TLR4-dependant transformation
such as hepatocarcinogenesis (Dapito et al., 2012). Both our
in vitro data showing TLR4 hyperresponsiveness in Dectin-1–/–
APC subsets and in HSCs and our in vivo data employing bone
marrow chimeric mice suggest that Dectin-1 signaling in both
the radio-sensitive and the radio-resistant compartments each
contribute toward the exacerbated fibrotic phenotype in Dec-
tin-1–/– liver. Importantly, HSCs may not be the only radio-resis-
tant cellular subset to contributing to augmented hepatic fibrosis
as recent work suggests that select subsets of liver macro-
phages are resistant to ablation by similar doses of total body
irradiation (Klein et al., 2007).
We found that the exacerbated hepatic fibrosis in Dectin-1–/–
liver, and augmented inflammation and toxicity in LPS-induced
sepsis inDectin-1–/– animals, is associatedwith elevated expres-
sion of TLR4 and its co-receptor CD14. This finding is particularly
notable as expression levels of TLR4 and CD14 are similar in WT
and Dectin-1–/– APC at baseline; however, in liver fibrosis, the
upsurge in TLR4 and CD14 expression—which we found to be
characteristic of toxin-induced hepatic injury—is muted in Dec-
tin-1-expressing APC. Similarly, instructive are the observations
that CD14 blockade mitigated the exacerbated hepatic fibrosis
and LPS-induced sepsis inDectin-1–/–mice but had negligible ef-
fects on liver fibrosis or systemic inflammation in WT animals.
Given the central position of CD14 in TLR4-mediated inflamma-
tory responses, this observation is surprising and suggests that
CD14 is dispensable for both intra- and extra-hepatic TLR4-
mediated inflammation in Dectin-1 competent hosts. These
unanticipated findings are in line with that of Tsung et al. who1918 Cell Reports 13, 1909–1921, December 1, 2015 ª2015 The Autfound that CD14-inhibition does not lessen HMGB1-mediated
hepatic ischemia-reperfusion injury in WT mice with otherwise
intact TLR4 signaling (Tsung et al., 2005). It is conceivable that
below a certain threshold CD14 level, CD14 expression indeed
dispensable in TLR4-mediated inflammation whereas above
this threshold level, CD14blockade suppresses TLR4 responses.
We show that, via TNF-a production, M-CSF is the mecha-
nistic influence for higher CD14 expression in activated Dec-
tin-1–/– innate inflammatory cells. Further, M-CSF along with its
receptor CD115 was robustly overexpressed in Dectin-1–/–
fibrotic liver in a PKC-dependent manner. In parallel with our ob-
servations employing CD14 blockade, M-CSF inhibition pro-
tected Dectin-1-deficient mice from hepatic fibrosis but had no
effect in lessening fibrotic injury in WT liver. Our current work
contrasts with a very recent report suggesting that, in HCV-
induced fibrosis, M-CSF plays a primary role in APC-mediated
fibrogenesis in cooperation with IL-34 (Preisser et al., 2014).
However, the signaling mechanisms governing HCV fibrosis
and toxin-mediated chronic liver injury are likely distinct.
Besides augmenting the M-CSF-CD14-TLR4 axis, another
possible mechanism for exacerbated hepatic fibrosis and ac-
celerated carcinogenesis in the context of Dectin-1 deletion
may relate to our recent finding that direct Dectin-1 ligation on
gdT cells drives hepatic regeneration (Rao et al., 2014). The dy-
namic process of liver fibrosis can be viewed as a physiological
‘‘struggle’’ between the drive for hepatocyte proliferation and
regeneration and, conversely, the deposition of ECM proteins
and collagen in place of non-viable hepatocytes. Liver rege-
neration—in both the context of partial hepatectomy and in
the setting of chronic liver disease—requires the secretion of
pro-regenerative cytokines (IL-6 and IL-22) from APC. These cy-
tokines, in turn, induce the phosphorylation of STAT3 in hepato-
cytes, leading to their proliferation (Li et al., 2002). However, the
triggers that promote the induction of a ‘‘regenerative pheno-
type’’ in hepatic inflammatory cells are incompletely understood.
We reported that yet-uncharacterized Dectin-1 ligands released
during liver regeneration bind CCL20-recruited gdT cells that, in
turn, release IL-22 and IL-17. IL-22 has direct mitogenic effects
on hepatocytes, and IL-17 induces a pro-regenerative pheno-
type in hepatic APC and other leukocytes (Rao et al., 2014;
Ren et al., 2010). It plausible that in liver fibrosis, akin to partial
hepatectomy, Dectin-1 ligation on gdT cells promotes hepato-
cyte proliferation in regenerative nodules. Consistent with this
notion, we found evidence of markedly reduced hepatocyte pro-
liferation in regenerative nodules in fibrotic Dectin-1–/– liver.
Further, a very recent report showed that chemokine-recruited
gdT cells mitigate hepatic fibrosis (Hammerich et al., 2014).
Hence, besides regulating TLR4 activation, Dectin-1 may
additionally limit liver fibrosis via gdT cell promotion of hepatic
regeneration. However, as in the case in partial hepatectomy,
identification of sterile Dectin-1 ligands in toxin-induced hepatic
fibrosis requires additional study.EXPERIMENTAL PROCEDURES
Animals and In Vivo Models of Liver Fibrosis, HCC, and Endotoxemia
C57BL/6 and CD45.1 mice were purchased from Jackson and bred in house.
Dectin-1–/– mice were a gift from Gordon Brown (University of Aberdeen).hors
Mincle/mice were obtained from the MMRRC. Age-matched 6- to 8-week-
old mice were used in all experiments. To induce hepatic fibrosis, female mice
were treated with thrice weekly injections of TAA (250 mg/kg; Sigma) for
12 weeks as described (Connolly et al., 2009). Alternatively, mice received
bi-weekly injections of CCl4 (0.5 ml/kg; Sigma) for the same duration. To
induce HCC, male mice were injected i.p. at 2 weeks of age with a single
dose of DEN (15 mg/kg, Sigma) followed by bi-weekly injections of CCl4
(0.2 ml/kg) starting at 8 weeks of age (Dapito et al., 2012). Mice were sacrificed
24weeks later. To induce endotoxemia, malemicewere injected i.p. with a sin-
gle dose of LPS (15 mg/kg; Sigma). Rectal core body temperature was deter-
mined using a MicroTherma 2 temperature probe (Thermoworks). In selected
experiments, MyD88 inhibitory peptide or control peptide (1 mg/kg, i.p.;
Novus), a-CD14 neutralizing antibody (4 mg/kg, i.p.; 4C1, BD Bioscience),
a small-molecule inhibitor of TLR4 (TAK-242, 4 mg/kg i.p.; Millipore), an
a-M-CSF neutralizing antibody (2mg/kg, i.p.; 5A1, BioXCell), recombinantmu-
rine M-CSF (250 mg/kg, i.v.; R&D Systems), Dectin-1 ligands Zymosan
depleted (40 mg/kg, i.p.), HKCA (2 3 109cells/kg, i.p.), WGP Dispersible
(8 mg/kg, i.p.), or Curdlan AL (8 mg/kg, i.p.; all Invivogen) were administered
immediately preceding each TAA or LPS administration. Serum liver enzymes,
including alanine aminotransferase (ALT) and aspartate aminotransferase
(AST), were determined using commercial kits (Sigma). M-CSF levels were
measured using the mouse M-CSF Quantikine ELISA Kit (R&D). Bone marrow
chimeric animals were created by irradiating mice (950 Rad) followed by i.v.
bone marrow transfer (1 3 107 cells) from non-irradiated donors as we have
described (Ochi et al., 2012b). Chimeric mice were employed in experiments
7 weeks later. All animal procedures were approved by the NYU School of
Medicine IACUC.
Human and Murine Cellular Isolation and Culture
Murine hepatic non-parenchymal cells (NPCs) were collected as previously
described (Connolly et al., 2009). Briefly, the portal vein was cannulated and
infused with 1% Collagenase IV (Sigma). The liver was then removed, minced,
and filtered to obtain single-cell suspensions. Hepatocyteswere excludedwith
serial low speed (400 rpm) centrifugation followed by high-speed (2,000 rpm)
centrifugation to isolate the NPC, which were then further enriched over a
40%Optiprep (Sigma) gradient. Human liverNPCswere isolatedusing a similar
protocol as we have described (Ibrahim et al., 2012). Human PBMCs were iso-
lated by overlaying whole blood diluted 1:1 in PBS over an equal amount of Fi-
coll. The cells were then spun at 2,100 rpm, and buffy coat was harvested to
obtain the PBMCs as described (Rehman et al., 2013). Single-cell suspensions
of murine splenocytes were generated by manual disruption of whole spleen
and red blood cell (RBC) lysis. For HSC isolation, the liver was perfused with
1% Collagenase IV, and HSCs were enriched over a 2-layer Nicodenz (Sigma)
gradient. HSCs were used for experiments on day 14 of culture. For cytokine
analysis, HSCs were cultured in complete medium (DNEM F12 with 10%
heat-inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml
streptomycin) at a concentration of 13106 cells/ml for 24 hr before supernatant
harvest and analysis using a cytometric bead array according the manufac-
tures’ protocol (BD Biosciences). In vitro proliferation was measured using
the XTT cell proliferation kit (Roche). PKC activity was measured using a PKC
Kinase Activity Assay Kit (Abcam). In selected experiments, cellular
activation was accomplished using LPS-EB Ultrapure (10 mg/ml), HKLM
(108 cell/ml), HKCA (108 cells/ml), Zymosan Depleted (100 mg/ml), WGP
Dispersible (100 mg/ml), Curdlan AL (100 mg/ml; all Invivogen), or recombinant
murine M-CSF (100 ng/ml; R&D). In select experiments, cells were treated
with mAbs directed against CD14 (10 mg/ml; 4C1), TNF-a (5 mg/ml;
2E2; Sloan-Kettering Institute), or a selective inhibitor of Protein Kinase C
(GF109203X, 1 mM; Tocris Bioscience).
Flow Cytometry
Single-cell suspensions of liver or spleen cells or cultured HSCs were incu-
bated with Fc blocking reagent (BioLegend) for 10 min followed by 30 min in-
cubation with fluorescently conjugated mAbs directed against mouse CD11b
(M1/70), CD11c (N418), CD45 (30-F11), F/480 (BM8), Gr1 (RB6-8C5), CD115
(AFS98), and MHC II (M5/114.15.2; all BioLegend). Cells were also tested for
expression of Dectin-1 (2A11; Abcam), TLR4 (SA15-21; BioLegend), CD14
(Sa14-2; BioLegend), and TLR2 (6C2; eBiosciences). Human liver NPCs andCell RePBMCs were stained with mAbs directed against CD45 (HI30), CD14 (M5E2;
both BioLegend), or Dectin-1 (259931; R&D). For intracellular cytokine stain-
ing, liver NPC were incubated for 4 hr with Brefeldin A (1:1,000) before perme-
abilization of cells and staining using fluorescent conjugated mAbs against
murine TNF-a (MP6-XT22) or IL-6 (MP5-20F3; both BioLegend). Experiments
were performed using the LSRII cytometer (BD Biosciences), and analysis was
done using FlowJo software (Tree Star).
Histology, Immunohistochemistry, and Immunofluorescence
Liver tissues were fixed overnight in 10% formaldehyde and were embedded in
paraffin.Slideswere stainedwithH&E,Masson’sTrichrome,orPicricacid-Sirius
red. For immunohistochemical analysis, paraffin-embedded or frozen sections
were incubated with antibodies against mouse CD45 (30-F11; BD Bioscience),
CD68 (KP1; Abcam), MPO (Rabbit polyclonal; Abcam), Dectin-1 (R1-8g7; Inviv-
ogen), PCNA (PC10; BioLegend), TLR4 (Rabbit polyclonal; Abcam), a-SMA
(1A4; Abcam), Phalloidin (Cell Signaling Technology), or M-CSF (Rabbit poly-
clonal; Abcam). Human liver sections were stained with an antibody against
Dectin-1 (Rabbit polyclonal; Abcam) or CD11b (M1/70; BioLegend). Quantifica-
tion was performed by examining ten high-powered fields (HPFs) per slide.
Fibrosis was quantified based on Trichrome staining using a computerized
grid as described (Ochi et al., 2012a). Immunofluorescent imaging was per-
formed using a LSM 700 confocal microscope and an Axiovert camera (Zeiss).
Western Blotting and Immunoprecipitation
For western blotting, total protein was isolated from 75-mg liver tissue by ho-
mogenization in RIPA buffer with Complete Protease Inhibitor cocktail (Roche).
Proteins were separated from larger fragments by centrifugation at 14,0003 g.
After determining total protein by the Bradford protein assay, 10% polyacryl-
amide gels (NuPage, Invitrogen) were equiloaded, electrophoresed at 200 V,
electrotransferred to PVDF membranes, and probed with monoclonal anti-
bodies to b-actin, MMP2, MMP7, MMP9, TIMP2, TIMP7, p-Erk1/2, Erk1/2,
p-NF-kb, NF-kb, MyD88, TRAF6, TRIF, and pPDGFRa (all Cell Signaling Tech-
nology) using the manufacturer’s recommended concentrations. Blots were
developed by ECL (Thermo Scientific). For immunoprecipitation experiments,
TLR4orDectin-1wasprecipitatedwithproteinG-agarose. Immuno-precipitates
were re-suspended and heated in loading buffer under reduced condition and
resolvedby10%SDS-PAGEbefore transfer toPVDFmembranes. Thepresence
of the co-immunoprecipitated proteins were determined by western blotting.
mRNA Analysis
For PCRanalysis, total RNAwasextracted using theRNEasyMini Kit (QIAGEN),
andcDNAwasmadeusing theHighCapacityReverseTranscription kit (Applied
Biosystems). RT-PCR was performed for mouse CD14 and b-actin using
commercially availablepre-designedprimers (QIAGEN). For themouseFibrosis
PCR array, Oncogene PCR array, and Cytokine and Chemokine PCR array,
mRNAs were reverse transcribed into first-strand cDNA using an RT2miRNA
First-Strand Kit (all QIAGEN). RT2 SYBR Green/ROX Quantitative PCR Master
Mix (QIAGEN) was used for amplification and the samples were run on the Stra-
tagene Mx3005P. For Nanostring analysis, the nCounter mouse inflammation
panel was employed using the nCounter Analysis System (Nanostring).
Statistical Analysis
Data are presented as mean ± SEM. Survival was measured according to the
Kaplan-Meier method. Statistical significance was determined by the Stu-
dent’s t test and the log-rank test using GraphPad Prism 6 (GraphPad Soft-
ware). p values of <0.05 were considered significant.
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